Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
5.17
-0.04 (-0.77%)
At close: Apr 28, 2026, 4:00 PM EDT
5.17
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Foghorn Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 30.91 | 22.6 | 34.16 | 19.23 | 1.32 | |
| Revenue Growth (YoY) | 36.75% | -33.83% | 77.63% | 1357.77% | 206.74% | |
| Cost of Revenue | 85.47 | 94.53 | 109.69 | 105.62 | 80.33 | |
| Gross Profit | -54.56 | -71.93 | -75.53 | -86.39 | -79.01 | |
| Selling, General & Admin | 27.55 | 28.36 | 32.37 | 30.75 | 21.73 | |
| Operating Expenses | 27.55 | 28.36 | 32.37 | 30.75 | 21.73 | |
| Operating Income | -82.11 | -100.29 | -107.91 | -117.14 | -100.73 | |
| Interest Expense | - | - | - | - | -1.91 | |
| Interest & Investment Income | 8.75 | 11.9 | 10.88 | 5.68 | 0.06 | |
| Other Non Operating Income (Expenses) | 3.36 | 4.16 | 2.83 | 2.58 | 2.49 | |
| EBT Excluding Unusual Items | -70 | -84.22 | -94.2 | -108.88 | -100.09 | |
| Asset Writedown | -5.91 | -2.4 | - | - | - | |
| Other Unusual Items | 1.63 | - | - | - | -1.23 | |
| Pretax Income | -74.28 | -86.62 | -94.2 | -108.88 | -101.32 | |
| Income Tax Expense | - | - | 4.23 | - | - | |
| Net Income | -74.28 | -86.62 | -98.43 | -108.88 | -101.32 | |
| Net Income to Common | -74.28 | -86.62 | -98.43 | -108.88 | -101.32 | |
| Shares Outstanding (Basic) | 63 | 55 | 42 | 42 | 37 | |
| Shares Outstanding (Diluted) | 63 | 55 | 42 | 42 | 37 | |
| Shares Change (YoY) | 14.72% | 30.79% | 0.92% | 11.89% | 236.49% | |
| EPS (Basic) | -1.18 | -1.58 | -2.34 | -2.62 | -2.73 | |
| EPS (Diluted) | -1.18 | -1.58 | -2.34 | -2.62 | -2.73 | |
| Free Cash Flow | -86.15 | -101.31 | -119.33 | 192.4 | -53.56 | |
| Free Cash Flow Per Share | -1.37 | -1.84 | -2.84 | 4.63 | -1.44 | |
| Gross Margin | -176.51% | - | -221.15% | - | - | |
| Operating Margin | -265.64% | -443.70% | -315.93% | -609.20% | -7637.15% | |
| Profit Margin | -240.33% | -383.24% | -288.17% | -566.27% | -7681.58% | |
| Free Cash Flow Margin | -278.72% | -448.24% | -349.38% | 1000.63% | -4060.88% | |
| EBITDA | -78.78 | -97.17 | -104.46 | -113.82 | -97.51 | |
| EBITDA Margin | -254.86% | - | - | - | - | |
| D&A For EBITDA | 3.33 | 3.12 | 3.45 | 3.32 | 3.23 | |
| EBIT | -82.11 | -100.29 | -107.91 | -117.14 | -100.73 | |
| EBIT Margin | -265.64% | - | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.